Link to Home The birth dose [of hepatitis B vaccine] provides early protection to infants at risk for infection after the perinatal period. Administration of a birth dose has been associated with higher rates of on-time completion of the hepatitis B vaccine series. References
 
For users of pentavalent vaccines. Why Switch to Pentacel Vaccine?
Pentacel vaccine is the first and only DTaP-IPV/Hib vaccine. It is indicated for childhood immunization at 2, 4, 6, and 15-18 months of age.1

  • Pentacel vaccine contains the same 5 acellular pertussis antigens, manufactured by the same process, as DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Absorbed). But Pentacel vaccine contains twice as much inactivated PTa and 4 times as much FHAb as DAPTACEL vaccine1 Learn More


  • Pentacel vaccine offers comparable immunogenicity to separately administered DAPTACEL vaccine, ActHIB® (Haemophilus b Conjugate Vaccine [Tetanus Toxoid Conjugate]), and IPOL® (Poliovirus Vaccine Inactivated)1

  • A primary pertussis immunization series consists of 4 doses of Pentacel vaccine1

  • Children who have completed the 4-dose series with Pentacel vaccine should receive a fifth dose of DTaP at 4-6 years of age5



  • Safety established in more than 5000 infants 2-18 months of age who received at least 1 dose of Pentacel vaccine. The most common local and systemic adverse reactions to Pentacel vaccine include injection site redness, swelling, and tenderness; fever, fussiness, and crying1 Learn More


  • Fever reported at similar rates when compared with separately administered DAPTACEL, ActHIB, and IPOL vaccines1,6



  • Simplifies the schedule as the first and only DTaP-IPV/Hib vaccine6,7


  • May save up to 7 injections within the first 2 years of life6,7


  • More than 14 million doses distributed in Canada during a decade of use5
a PT = Detoxified pertussis toxin.
b FHA = Filamentous hemagglutinin.
c ACIP = Advisory Committee on Immunization Practices; AAP = American Academy of Pediatrics; AAFP = American Academy
of Family Physicians.

Indication
Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b. Pentacel vaccine is approved for use in children 6 weeks through 4 years of age (prior to fifth birthday).

Safety Information
The most common local and systemic adverse reactions to Pentacel vaccine include injection site redness, swelling, and tenderness; fever, fussiness, and crying. Other adverse reactions may occur. Known systemic hypersensitivity reaction to any component of Pentacel vaccine or a life-threatening reaction after previous administration of the vaccine or a vaccine containing the same substances are contraindications to vaccination.

The decision to give Pentacel vaccine should be based on the potential benefits and risks; if Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid; or if adverse events have occurred in temporal relation to receipt of pertussis-containing vaccine. Encephalopathy within 7 days of administration of a previous dose of a pertussis-containing vaccine or a progressive neurologic disorder is a contraindication. Vaccination with Pentacel vaccine may not protect all individuals.

Before administering Pentacel vaccine, please see accompanying full Prescribing Information.

Copyright © 2009 Sanofi Pasteur Inc. Privacy Policy | Legal Notice | Safety Information | Site Map This page last updated 04.17.2009 References